To read the full story, subscribe or sign in.

Wyeth Exits Deal For FluMist, Gives MedImmune Full Rights

April 28, 2004

By Karen Carey

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 16, 2025.

Vitesse finesse pays off: DBV wins in peanut allergy phase III

BioWorld

DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....

Harbour Biomed closes busy year with $1B+ BMS deal

BioWorld

Harbour Biomed has added another collaboration to its end-of-year dealmaking, this time with Bristol Myers Squibb Co. (BMS) to develop multispecific antibodies....

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...